QuadraMune(TM) is a nutritional supplement which has previously been demonstrated to possess antiinflammatory and immune modulatory activity based on in vitro and pilot in vivo studies. The current clinical trial aims to assess in a 500 volunteer trial the efficacy of QuadraMune(TM) in reducing infection in individuals at high risk of COVID-19.
QuadraMune(TM) is composed of 4 natural ingredients. Pterostilbene is an analogue of resveratrol, and has been shown to possess antiinflammatory activity. Additionally, this compound suppresses macrophage activation while enhancing NK activity. Epigallocatechin gallate (EGCG) is one of the active ingredients in green tea and has been shown to act as an activator of T cells, and a suppressor of neutrophil mediated inflammation. Sulforaphane is derived from broccoli and studies have shown that it protects lungs from inflammatory pathology. Thymoquinone, which is chemically related to hydroxychloroquine, possessing antiviral effects and increases NK activity. QuadraMune is a combination of these ingredients and is believed to possess superior in vitro and in vivo therapeutic properties as compared to when the ingredients are administered individually. The study aims to assess preventative effects of QuadraMune(TM) administration for 12 weeks.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
500
QuadraMune(TM) is a commercially available nutritional supplement
Therapeutic Solutions International
Oceanside, California, United States
RECRUITINGPrevention of COVID-19
Prevention of COVID-19 symptoms as recorded in a daily diary
Time frame: 12 Weeks
Safety as determined by presence or absence of Adverse Events and Serious Adverse Events
Assessment of adverse events and serious adverse events will be performed.
Time frame: 12 Weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.